Sentinel lymph node biopsy in thin melanoma patients

Journal of Histotechnology

Volumn 28, Issue 4, 2006, Pages 279-285

  Hershko, Dan D ^a   Robb, Bruce W ^b   Lowy, Andrew M ^b   Ahmad, Syed A ^b   Ramadas, Go H ^b   Soldano, Debbie A ^b   Sussman, Jeffrey J ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Early diagnosis; Incidence; Melanoma; Neoplasm staging; Sentinel lymph node biopsy

Indexed keywords

ADULT; AGE; ARTICLE; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; GENDER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TUMOR LOCALIZATION; AGED; EARLY DIAGNOSIS; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

DIAGNOSTIC AGENT; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TECHNETIUM TC 99M SULFUR COLLOID;

EID: 33644698050     PISSN: 01478885     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20415     Document Type: Article

References (50)

1. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multiinstitutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
2. Bieligk SC, Ghossein R, Bhattacharya S, et al.: Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999;6:232-240.
3. Morton DL, Hoon DS, Cochran AJ, et al.: Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-549; discussion 549-550.
4. Blaheta HJ, Ellwanger U, Schittek B, et al.: Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-642.
5. Bostick PJ, Morton DL, Turner RR, et al.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-3244.
6. Shivers SC, Wang X, Li W, et al.: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 1998;280:1410-1415.
7. Shivers S, Alsarraj M, Guiliano R, et al.: Molecular staging of melanoma. Ann Surg Oncol 2004;11:953-954.
8. Gradilone A, Ribuffo D, Silvestri I, et al.: Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: Prognostic significance. Ann Surg Oncol 2004;11:983-987.
9. Wlodzimierz R, Rutkowski P, Nowecki ZI, et al.: Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay. Ann Surg Oncol 2004;11:988-997.
10. Corsetti RL, Allen HM, Wanebo HJ: Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000;7:456-460.
11. Gimotty PA, Guerry D, Ming ME, et al.: Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004;22:3668-3676.
12. Breslow A, Macht SD: Evaluation of prognosis in Stage I cutaneous melanoma. Plast Reconstr Surg 1978;61:342-346.
13. Concensus statement. Diagnosis and treatment of early melanoma. In "NIH Consensus Development Conference."
14. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
15. Buzaid AC, Ross MI, Balch CM, et al.: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-1051.
16. McKinnon JG, Yu XQ, McCarthy WH, et al.: Prognosis for patients with thin cutaneous melanoma: Long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003;98:1223-1231.
17. King R, Googe PB, Mihm MC, Jr.: Thin melanomas. Clin Lab Med 2000;20:713-729.
18. Gromet MA, Epstein WL, Blois MS: The regressing thin malignant melanoma: A distinctive lesion with metastatic potential. Cancer 1978;42:2282-2292.
19. Naruns PL, Nizze JA, Cochran AJ, et al.: Recurrence potential of thin primary melanomas. Cancer 1986;57:545-548.
20. Finley JW, Gibbs JF, Rodriguez LM, et al.: Pathologic and clinical features influencing outcome of thin cutaneous melanoma: Correlation with newly proposed staging system. Am Surg 2000;66:527-531; discussion 522-531.
21. Graham CH, Rivers J, Kerbel RS, et al.: Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994;145:510-514.
22. Shaw HM, McCarthy WH, McCarthy SW, et al.: Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147-1150.
23. Bedrosian I, Faries MB, Guerry DT, et al.: Incidence of sentinel node metastasis in patients with thin primary melanoma (
24. Pontikes LA, Temple WJ, Cassar SL, et al.: Influence of level and depth on recurrence rate in thin melanomas. Am J Surg 1993;165:225-228.
25. Slingluff CL, Jr., Vollmer RT, Reintgen DS, et al.: Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 1988;208:150-161.
26. Kelly JW, Sagebiel RW, Clyman S, et al.: Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985;202:98-103.
27. Andersson AP, Dahlstrom KK, Drzewiecki KT: Prognosis of thin cutaneous head and neck melanoma (<1 mm). Eur J Surg Oncol 1996;22:55-57.
28. Park KG, Blessing K, McLaren KM, et al: A study of thin (<1.5 mm) malignant melanomas with poor prognosis. Br J Plast Surg 1993;46:607-610.
29. Vilmer C, Bailly C, Le Doussal V, et al.: Thin melanomas with unusual aggressive behavior: A report on nine cases. Melanoma Group of French Federation of Cancer Centers. J Am Acad Dermatol 1996;34:439-444.
30. Blessing K, McLaren KM, McLean A, et al.: Thin malignant melanomas (less than 1.5 mm) with metastasis: A histological study and survival analysis. Histopathology 1990;17:389-395.
31. Ronan SG, Eng AM, Briele HA, et al.: Thin malignant melanomas with regression and metastases. Arch Dermatol 1987;123:1326-1330.
32. Massi D, Franchi A, Borgognoni L, et al.: Thin cutaneous malignant melanomas (
33. Frahm SO, Schubert C, Parwaresch R, et al.: High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 2001;32:1376-1381.
34. Guitart J, Lowe L, Piepkorn M, et al.: Histological characteristics of metastasizing thin melanomas: A case-control study of 43 cases. Arch Dermatol 2002;138:603-608.
35. Schmid-Wendtner MH, Baumert J, Eberle J, et al.: Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): Clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol 2003;149:788-793.
36. Olah J, Gyulai R, Korom I, et al.: Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003;149:662-663.
37. Cook MG, Spatz A, Brocker EB, et al.: Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol 2002;197:188-193.
38. Balch CM, Soong SJ, Bartolucci AA, et al.: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-263; discussion 256-263.
39. Gershenwald JE, Colome MI, Lee JE, et al.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-2260.
40. Takeuchi H, Morton DL, Kuo C, et al.: Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22:2671-2680.
41. Kammula US, Ghossein R, Bhattacharya S, et al.: Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004;22:3989-3996.
42. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al.: Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003;36:347-350.
43. Agnese DM, Abdessalam SF, Burak WE Jr., et al.: Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134:542-547; discussion 547-548.
44. Bleicher RJ, Essner R, Foshag LJ, et al.: Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:1326-1331.
45. Jacobs IA, Chang CK, DasGupta TK, et al.: Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol 2003;10:558-561.
46. Nahabedian MY, Tufaro AP, Manson PN: Sentinel lymph node biopsy for the T1 (thin) melanoma: Is it necessary? Ann Plast Surg 2003;50:601-606.
47. Lowe JB, Hurst E, Moley JF, et al.: Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003;139:617-621.
48. Sondak VK, Taylor JM, Sabel MS, et al.: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-258.
49. Stitzenberg KB, Groben PA, Stern SL, et al.: Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or = 1.0 mm). Ann Surg Oncol 2004;11:900-906.
50. Tsao H, Cosimi AB, Sober AJ: Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997;79:2361-2370.